Stock Track | Insmed Soars 5.13% as RBC Capital Markets Defends Stock After Post-Earnings Sell-off

Stock Track

May 13

Insmed's stock surged 5.13% during Tuesday's trading session, marking a significant rebound for the pharmaceutical company.

The price increase follows analysis from RBC Capital Markets, which defended the stock by stating that the sell-off after its first-quarter earnings report was overdone. RBC maintained its full-year 2026 sales guidance for Brinsupri, Insmed's non-cystic fibrosis bronchiectasis treatment, at approximately $1.3 billion and kept its Outperform rating on the stock.

Despite Insmed's Q1 results beating expectations with net product revenue of $306 million versus estimates of $300.8 million, the stock had initially sold off on investor concerns about patient addition trends and compliance rates. RBC's assessment that organic patient additions should enable the treatment to clear the $1 billion threshold with cushion prompted the stock's recovery during the trading day.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1171513000"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1171513000\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1171513000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 08:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171513000","market":"nz","top_or_hot":-1,"title":"Stock Track | Insmed Soars 5.13% as RBC Capital Markets Defends Stock After Post-Earnings Sell-off","media":"Stock Track","content":"<p>Insmed's stock surged 5.13% during Tuesday's trading session, marking a significant rebound for the pharmaceutical company.</p><p>The price increase follows analysis from RBC Capital Markets, which defended the stock by stating that the sell-off after its first-quarter earnings report was overdone. RBC maintained its full-year 2026 sales guidance for Brinsupri, Insmed's non-cystic fibrosis bronchiectasis treatment, at approximately $1.3 billion and kept its Outperform rating on the stock.</p><p>Despite Insmed's Q1 results beating expectations with net product revenue of $306 million versus estimates of $300.8 million, the stock had initially sold off on investor concerns about patient addition trends and compliance rates. RBC's assessment that organic patient additions should enable the treatment to clear the $1 billion threshold with cushion prompted the stock's recovery during the trading day.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insmed Soars 5.13% as RBC Capital Markets Defends Stock After Post-Earnings Sell-off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insmed Soars 5.13% as RBC Capital Markets Defends Stock After Post-Earnings Sell-off\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-13 08:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insmed's stock surged 5.13% during Tuesday's trading session, marking a significant rebound for the pharmaceutical company.</p><p>The price increase follows analysis from RBC Capital Markets, which defended the stock by stating that the sell-off after its first-quarter earnings report was overdone. RBC maintained its full-year 2026 sales guidance for Brinsupri, Insmed's non-cystic fibrosis bronchiectasis treatment, at approximately $1.3 billion and kept its Outperform rating on the stock.</p><p>Despite Insmed's Q1 results beating expectations with net product revenue of $306 million versus estimates of $300.8 million, the stock had initially sold off on investor concerns about patient addition trends and compliance rates. RBC's assessment that organic patient additions should enable the treatment to clear the $1 billion threshold with cushion prompted the stock's recovery during the trading day.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1171513000","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171513000","pubTimestamp":1778633126,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insmed's stock surged 5.13% during Tuesday's trading session, marking a significant rebound for the pharmaceutical company.The price increase follows analysis from RBC Capital Markets, which defended...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"股票追踪|Insmed飙升5.13%，加拿大皇家银行资本市场在财报后抛售后捍卫股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"Insmed's stock surged 5.13% during Tuesday's trading session, marking a significant rebound for the pharmaceutical company.The price increase follows analysis from RBC Capital Markets, which defended the stock by stating that the sell-off after its first-quarter earnings report was overdone. RBC maintained its full-year 2026 sales guidance for Brinsupri, Insmed's non-cystic fibrosis bronchiectasis treatment, at approximately $1.3 billion and kept its Outperform rating on the stock.Despite Insmed's Q1 results beating expectations with net product revenue of $306 million versus estimates of $300.8 million, the stock had initially sold off on investor concerns about patient addition trends and compliance rates. RBC's assessment that organic patient additions should enable the treatment to clear the $1 billion threshold with cushion prompted the stock's recovery during the trading day.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}